Home › Cases › Hypercalcaemia — Primary Hyperparathyroidism
Hypercalcaemia
Hypercalcaemia — Primary Hyperparathyroidism
6 questions
Question 1 · PHPT presentation
Correct answer: Refer for parathyroid surgery; also check DXA, renal ultrasound, renal function and urinary calcium
Why
With confirmed PHPT, Ca 2.96 mmol/L and constipation/polyuria meet NICE surgical referral criteria. Also assess bone and renal involvement and exclude FHH. NICE recommends referral for symptoms, Ca ≥2.85, renal stones, fragility fracture or osteoporosis; consider referral even without these. Memory aid: bones = osteitis fibrosa cystica; stones = renal calculi; abdominal groans = constipation/peptic ulcer; psychic moans = mood and cognitive changes.
Key point
PHPT + symptoms or adjusted Ca ≥2.85 → parathyroid-surgery referral. Bone/renal complications are separate indications.
Question 2 · Localisation
Correct answer: Neck US, then consider Tc-99m sestamibi if useful; after two negative/discordant studies use expert 4-gland exploration rather than more routine imaging. No IOPTH for first-time surgery
Why
NICE first-time PHPT surgery:
- Neck US if it informs the approach; consider Tc-99m sestamibi second (uptake in hyperfunctioning tissue)
- A single localised adenoma permits a choice of focused surgery or 4-gland exploration
- Both studies negative/discordant: no further routine imaging; expert 4-gland exploration (offer if non-localising, consider if discordant)
- No intraoperative PTH monitoring in first-time surgery under NICE
- Reoperative/specialist: 4DCT, MRI, 11C-methionine PET, IOPTH. Miami: ≥50% PTH fall at 10 min from the higher pre-incision/pre-excision value predicts, not guarantees, cure
Key point
NICE first operation: US ± sestamibi; if both negative/discordant, expert 4-gland exploration — no more routine imaging, no IOPTH.
Question 3 · MEN syndromes
Correct answer: Young age + PHPT: screen for MEN1 (Multiple Endocrine Neoplasia) — pituitary tumour + PHPT + pancreatic tumours (insulinoma, gastrinoma). Genetic testing (MENIN mutation)
Why
MEN1 (Werner syndrome): MENIN tumour suppressor gene (chromosome 11q13). Triad:
- PHPT (90-100% — most common manifestation)
- Pancreatic/duodenal NETs (gastrinoma — Zollinger-Ellison, insulinoma)
- Anterior pituitary tumours (prolactinoma most common)
MEN2A: MTC + phaeochromocytoma + PHPT. Young/familial PHPT: genetic testing.
Key point
Young PHPT: screen for MEN1 (PHPT + pituitary + pancreatic NETs). MEN2A: MTC + phaeo + PHPT. Genetic testing (MENIN mutation).
Question 4 · Post-op hungry bone syndrome
Correct answer: Hungry bone syndrome — after prolonged PTH excess, skeleton is calcium-hungry. Rapid calcium uptake into bone after PTH removal → severe hypocalcaemia
Why
Hungry bone syndrome: after parathyroidectomy (especially severe pre-op bone disease), rapid calcium + phosphate flux into bone → severe hypocalcaemia (and hypophosphataemia). Treatment: IV calcium gluconate infusion + high-dose oral calcium + calcitriol. Can last days-weeks. Risk factors: pre-op high ALP (bone turnover markers), severe hypercalcaemia, large adenoma.
Key point
Hungry bone syndrome: severe hypoCa post-parathyroidectomy. Bone avid for calcium. IV calcium gluconate + oral calcium + calcitriol.
Question 5 · Cinacalcet
Correct answer: Cinacalcet (calcimimetic): allosteric activator of calcium-sensing receptor (CaSR) → reduces PTH secretion. Lowers Ca2+ and PTH, but does not improve bone density. Bisphosphonates for bone protection
Why
Cinacalcet (Sensipar): calcimimetic — activates CaSR on parathyroid cells, sensitises to calcium → suppresses PTH. Reduces serum Ca2+ but does NOT improve bone density (surgery does). Used: surgery-declined/unfit patients, MEN1, parathyroid carcinoma. Side effects: nausea, hypocalcaemia. Bisphosphonates (alendronate) improve bone density.
Key point
Cinacalcet: reduces Ca2+ but not bone density (surgery superior). MEN1, inoperable, surgery-declined patients.
Question 6 · Parathyroid carcinoma
Correct answer: Parathyroid carcinoma: very high Ca2+ + very high PTH (often >10x upper limit) + palpable neck mass + fibrous bands on histology. Rare (1% of PHPT)
Why
Parathyroid carcinoma: very rare (1%). Features: Ca2+ often >3.5, PTH massively elevated (3-10x ULN), palpable neck mass (atypical for adenoma), recurrence after surgery. CDC73 (formerly HRPT2; encodes parafibromin) mutations. En-bloc resection (thyroid lobe + ipsilateral lymph nodes). No effective chemotherapy/radiation. Cinacalcet for hypercalcaemia control in unresectable disease.
Key point
Parathyroid carcinoma: very high Ca2+ + massively high PTH + palpable mass. En-bloc resection. HRPT2 mutation. 1% of PHPT.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.